RepliCel Life Sciences Inc. (TSXV:RP)

RepliCel Life Sciences Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.35	0.35	0.35	0.35	0.35	0.35
Revenue Growth (YoY)	0%	0%	0%	0%	0%	110.98%
Gross Profit	0.35	0.35	0.35	0.35	0.35	0.35
Selling, General & Admin	0.66	1.21	1.13	1.51	0.88	1.08
Research & Development	0.27	0.53	0.62	1.15	0.82	2.2
Operating Expenses	0.93	1.74	1.75	2.66	1.7	3.28
Operating Income	-0.57	-1.39	-1.4	-2.3	-1.35	-2.93
Interest Expense	-0.1	-0.15	-0.08	-0.14	-0.07	-0.03
Interest & Investment Income	0	0	0	0	0	-
Currency Exchange Gain (Loss)	0.1	0.01	-0.29	-0.05	-0.01	-0.01
Other Non Operating Income (Expenses)	2.03	1.3	1.02	-1.62	-0.18	-0.14
EBT Excluding Unusual Items	1.46	-0.22	-0.75	-4.11	-1.6	-3.11
Other Unusual Items	-0.1	-0.1	0	0.03	0.02	0.11
Pretax Income	1.37	-0.31	-0.74	-4.07	-1.58	-3
Net Income	1.37	-0.31	-0.74	-4.07	-1.58	-3
Net Income to Common	1.37	-0.31	-0.74	-4.07	-1.58	-3
Shares Outstanding (Basic)	70	59	38	32	27	24
Shares Outstanding (Diluted)	70	59	38	32	27	24
Shares Change (YoY)	52.12%	56.86%	16.26%	20.50%	11.84%	10.31%
EPS (Basic)	0.02	-0.01	-0.02	-0.13	-0.06	-0.12
EPS (Diluted)	0.02	-0.01	-0.02	-0.13	-0.06	-0.12
Free Cash Flow	-0.09	-1.41	-1.41	-2.51	-0.77	-2.78
Free Cash Flow Per Share	-0.00	-0.02	-0.04	-0.08	-0.03	-0.12
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-162.27%	-391.89%	-394.51%	-650.57%	-381.75%	-827.41%
Profit Margin	386.01%	-88.13%	-210.11%	-1151.52%	-446.74%	-849.27%
Free Cash Flow Margin	-24.94%	-399.76%	-398.45%	-710.66%	-216.32%	-786.42%
EBITDA	-0.57	-1.38	-1.39	-2.3	-1.35	-2.92
EBITDA Margin	-162.08%	-	-	-	-	-
D&A For EBITDA	0	0	0	0	0	0
EBIT	-0.57	-1.39	-1.4	-2.3	-1.35	-2.93
EBIT Margin	-162.27%	-	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.